Brief: Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results Demonstrating Substantial Increases In Complete Response Rates In Advanced Cutaneous Squamous Cell Carcinoma
27/07/2023 12:09
July 27 (Reuters) - Checkpoint Therapeutics Inc
CKPT.O :
* CHECKPOINT THERAPEUTICS ANNOUNCES COSIBELIMAB LONGER-TERM
RESULTS DEMONSTRATING SUBSTANTIAL INCREASES IN COMPLETE RESPONSE
RATES IN ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA
* CHECKPOINT THERAPEUTICS INC - COSIBELIMAB CONTINUES TO
DEMONSTRATE A FAVORABLE SAFETY PROFILE
* CHECKPOINT THERAPEUTICS INC - BIOLOGICS LICENSE
APPLICATION
CURRENTLY UNDER REVIEW BY U.S. FDA; PDUFA GOAL DATE OF JANUARY
3, 2024
Source text for Eikon: ID:nGNX5HTGrD
Further company coverage: CKPT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fortress Biotech
See all newsFortress Biotech Inc reports results for the quarter ended June 30 - Earnings Summary
Fortress Biotech Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Fortress Biotech And Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing
Fortress Biotech Q1 net income jumps on PRV sale
Brief: Journey Medical Corporation Secures Contract With Third Major Gpo For Emrosi